COVID-19 clinical trials: learning from exceptions in the research chaos

Nat Med. 2020 Nov;26(11):1671-1672. doi: 10.1038/s41591-020-1077-z.

Authors

Kari A O Tikkinen^{1

2}, Reza Malekzadeh³, Martin Schlegel⁴, Jarno Rutanen⁵, Paul Glasziou⁶

Affiliations

¹ Departments of Urology and Public Health, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
² Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland.
³ Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Anesthesiology and Intensive Care, Technical University of Munich School of Medicine, Munich, Germany.
⁵ Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
⁶ Institute for Evidence-Based Healthcare, Bond University, Robina, Australia. pglaszio@bond.edu.au.

PMID: 32963376
DOI: 10.1038/s41591-020-1077-z

No abstract available

Publication types

Historical Article
Letter

MeSH terms

Biomedical Research / history
Biomedical Research / organization & administration*
Biomedical Research / standards
COVID-19 / diagnosis
COVID-19 / epidemiology
COVID-19 / therapy*
Canada / epidemiology
Clinical Trials as Topic* / methods
Clinical Trials as Topic* / organization & administration
Clinical Trials as Topic* / standards
Community Networks / organization & administration
Community Networks / standards
Drug Evaluation, Preclinical / methods
Drug Evaluation, Preclinical / standards
Europe / epidemiology
History, 21st Century
Humans
International Cooperation
Learning
Neural Networks, Computer
Organizational Innovation
Pandemics* / history
Patient Selection
Pragmatic Clinical Trials as Topic / methods
Pragmatic Clinical Trials as Topic / standards
Research Design
Scandinavian and Nordic Countries / epidemiology
United Kingdom / epidemiology
World Health Organization / organization & administration